研究单位：[1]Eli Lilly and Company[2]The First People's Hospital of Yunnan Province Kunming,Yunnan,China,650034[3]Chongqing General Hospital Chongqing,Yuzhong District,China,400014[4]Zhejiang Hospital Hangzhou,Zhejiang,China,310013[5]Beijing Pinggu District Hospital Beijing,China,101200[6]Tianjin Medical University General Hospital Tianjin,Tianjin,China,300052[7]The Affiliated Jiangyin Hospital of Southeast University Medical College Wuxi Shi,Wuxi Shi,China,214400[8]West China Hospital Sichuan University Chengdu,Sichuan,China,610041
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
